Skip to main content
TipRanks
Go Ultimate75% OFF

Enveric Biosciences (SLZ0) Stock Price & Analysis

1 Followers

SLZ0 Stock Chart & Stats

€4.67€0.00(0.00%)
At close: 5:30 PM GMT+1
€6.5€7€7.5Oct 21Oct 30Nov 12
Day’s Range
EUR 4.67 - EUR 4.79
52-Week Range
EUR 4.67 - EUR 4.79
Previous Close
EUR 4.67
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 6.15M
Enterprise Value
EUR 1.05M
Total Cash (Recent Filing)
EUR 5.61M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
-1.11
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

The absence of debt limits fixed financial obligations and reduces solvency and refinancing pressure while the company funds drug discovery and development. This gives management more flexibility than leveraged peers, although it does not eliminate the need for future capital.

Improved Equity Base

Growth in equity provides a larger capital cushion for ongoing research and development than the company had in 2024. A stronger equity base can improve financial resilience, though the cushion remains modest relative to continuing losses and cash requirements.

Lower Operating Losses

Improving operating losses indicate some progress toward controlling the cost base as the development platform advances. If sustained, this trend could extend the company’s financial runway and reduce the amount of capital required to support future clinical and preclinical work.

Bears Say

No Commercial Revenue

Zero reported revenue shows that Enveric has not yet reached meaningful commercial scale or established a self-funding product base. Its financial outlook therefore remains dependent on successful development and eventual commercialization of drug candidates rather than current operating sales.

Persistent Cash Burn

Persistent negative operating and free cash flow means research activities continue to consume cash rather than fund themselves. This structurally increases reliance on external financing and leaves less flexibility to absorb development delays, sustain trials, or advance multiple candidates.

Large Losses And Thin Capital

The sizable ongoing loss relative to the company’s equity base highlights limited financial scale and weak current returns on invested capital. Continued losses can erode the capital cushion over time and increase the importance of obtaining funding to maintain development operations.

Enveric Biosciences News

SLZ0 FAQ

What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was €4.67 and its highest was €4.79 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is €6.15M.
When is Enveric Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Nov 12, 2026. The company reported -€0.516 earnings per share for the quarter.
Is Enveric Biosciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 4,475,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -€0.516 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in DE:SLZ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology